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SUMMARY.-Individual tolerance to single or widely spaced doses of metho-
trexate was explored in 49 patients with advanced cancer with normal serum
creatinine and/or blood urea nitrogen. Methotrexate was given as an intra-
venous infusion over 1 hour at initial doses of80-120 mg./m2body surface area.
The doses were increased by 50% increments every 2 weeks until moderate
toxicity occurred, arbitrarily defined as leukopenia < 5000/mm.3, and/or
thrombocytopenia < 100,000/mm.3, and/or the appearance of oral mucous or
intestinal toxicity.
The individual dose required to produce initial evidence oftoxicityvariedbya
factor of 18 between 50 and 900 mg./m2. Starting doses above 80 mg./m2 were
potentially hazardous. Dose limiting toxicity consisted of leukopenia with or
without stomatitis in 81% of the patients, and stomatitis without leukopenia,
in 19%. Thrombocytopenia was seen in 19% of the patients, but was never a
dose limiting factor alone. Leukopenia always preceded thrombocytopenia.
The nadir for haematologic toxicity varied considerably between day 5-15
and 9-14 for leukocytes and platelets, respectively, while oral ulcerations, when
they occurred, consistently began between days 3-6 after drug administration.
Other toxic manifestations included dermatologic changes in8 patients, hepatic
dysfunction in 7, conjunctivitis in 7, nausea and vomiting in 6, alopecia in 4,
and diarrhea in 3 patients.
The only factor which predicted toxicity was the patient's age. Drug
tolerance was independent of previous chemotherapy or radiotherapy, weight
loss, serum albumin or pretreatment serum folic acid levels.
SINCE the folic acid analogues were introduced as antineoplastic agents in
1948 by Farber et al., a variety of dose schedules have been explored. Goldin
and his colleages reported 2 methods ofimproving the therapeutic index ofmetho-
trexate (MTX) as measured by the prolongation ofsurvival of CDBA hybrid mice
with Leukaemia 1210. The first method consisted of administration ofMTX
every fourth day rather than twice daily, once daily, or every second day (Goldin,
Venditti, Humphreys and Mantel, 1956). The superiority of this dose schedule
of MTX over daily medication was confirmed for maintenance of remission in
childhood leukaemia (Acute Leukaemia Group B, 1965). The second method
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included sequential use of MTX and leukovorin (N5-formyl tetrahydrofolic acid,
citrovorum factor, folinic acid) in order to facilitate recovery of vital host cells at
a time when tumour cells werepresumablyirreversiblydamaged (Goldin, Venditti,
Kline, and Mantel, 1966).
Therefore the present study was designed to define the individual tolerance to
single orwidely spaced doses ofMTX, as a baseline for exploration ofthe optimal
time interval and dose ratio ofMTX followed by leukovorin (Selawry, 1970).
MATERIALS AND METHODS
Forty-nine patients with histologically confirmed diagnosis of cancer were
placed under study. Eleven patients were studied at Roswell Park Memorial
Institute, 6 patients at West Tennessee Chest Disease Hospital, and the
remaining 37 patients at the NCI-VA Medical Oncology Service, V.A. Hospital,
Washington, D.C. The disease in each patient was considered incurable by
surgery and not controllable by radiotherapy or conventional chemotherapy.
None of the patients had previously received MTX. Initial white blood count
above 5000/mm.3, thrombocytes above 200,000/mm.3, normal renal function as
measuredby blood ureanitrogen (BUN) < 25mg./100 ml. and/or serum creatinine
< 1-5 mg./100 ml. and absence of oedema, pleural or peritoneal effusion were all
mandatory before exposure to MTX. Serum folic acid activity was determined
before treatment using a microbiological assay (normal values 3-2-15-0 ng./ml.)
(Grossowitz et al., 1962). For 2 weeksfollowing MTX administration, or longer if
recoveryfromtoxicity wasdelayed,haematocrit, WBC, reticulocytes, andplatelets
were obtained at least twice weekly, while chemical parameters such as BUN,
serum bilirubin, serum alkaline phosphatase, serum glutamic oxalic acid trans-
aminase (SGOT) and serum globulin and albumin were monitored at least once
weekly. Nutritional status was gauged by weight loss from the onset of the
neoplastic disease until the time of drug administration. MTX was given intra-
venously in 500 ml. of 5% dextrose in water solution as a 1-hour infusion.
Initially, 3 patients were evaluated at a starting dose of 80 mg./m2. Because
no toxicity was encountered, additional patients were evaluated at starting dose
levels of 120 mg.m2 (3 patients) and 180 mg./m2 (2 patients). At this point, the
wide individual variation of tolerance to MTX was recognized, and the initial
dose was subsequently reduced again to 120 mg./m2 and later to 80 mg./m2.
In 1 patient who developed severe haematologic toxicity at 80 mg./m2, a dose of
50 mg./m2 was explored. As a result of this experience in the first 11 patients,
a starting dose of 80 mg./m2 was selected for all subsequent patients studied.
The dose was increased by 50% every 2 weeks until moderate toxicity occurred,
arbitrarily defined by either a decrease of WBC to < 5000/mm.3, platelets to
< 100,000/mm.3, or the occurrence of oral or other toxicity.
Measurability oftumour was not aprerequisite for entryinto the studybecause
the study was designed primarily for determination ofhost tolerance. Neverthe-
less, serial measurements of accessible tumour were obtained wherever possible.
Tumour size was approximated by the products of the longest and the widest
perpendicular diameters as measured by calipers. A response was considered
complete when there was total disappearance ofall measureable lesions and partial
when there was a decrease of more than 50 %in tumour size in the absence ofnew
or increasing lesions elsewhere. Progression was defined as an increase of more
than 50 %ofsize ofany tumour lesions or the occurrence ofanynewlesions.
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RESULTS
Variability of host tolerance.-The individual toxic dose for a single 1-hour
infusion of MTX in the 49 patients varied by a factor of 18 from a minimum of
50 mg./m2 to a maximum of 900 mg./m2 (Table I). The median toxic dose was
TABLE I.-Common Manifestations of MTX Toxicity
Stomatitis
Haematologic toxicity
A
Dose Number of ,_- _ __ -_ __As only dose
of MTX of toxic WBC Thrombocytes limiting
(mg./ml) patients < 5000 mm.3 < 100,000 mm.3 Total manifestation
50 . 1 . 1 0 . 1 0
80 . 11 . 8 1 5 3
120 . 15 . 13 3 . 5 2
180 . 8 8 2 . 4 0
270 . 7 5 1 . 3 2
400 . 4 3 1 . 2 1
600 . 2 1 1 . 2 1
900 . 1 . 1 0 . 0 0
Total . 49 . 40 9 . 22 9
MTX was administered as a 1-hour infusion in 50 per cent increments every 2 weeks until individual
tolerance was reached.
120 mg./m2. Four patients expired at the time of pronounced haematologic
(3 patients) and 180 mg./m2 (1 patient). Thepatients arediscussedindetailbelow.
Tables I and II indicate the incidence of various types of toxicity as related to
TABLE II.-Less Common Manifestations of MTX Toxicity
Dose Number of Nausea
of MTX toxic Dermatologic Hepatic Conjunc- and
(mg./m2) patients toxicity toxicity tivitis vomiting Alopecia Diarrhea
50 . 1 . 3 . . . . - .
80 . 11 . 1 . 1 . . 1 . 1 . 1
120 . 15 . 3 . 3 . 2 I 1
180 . 8 . 1 I . 1 . 1 . 1
270 . 7 . - . 1 . . 1 . 1 . 1
400 . 4 . - . - . 2 . - 1 -
600 . 2 . 2 . 1 . 2 . 2
900 . 1
Total . 49 . 8 . 7 . 7 . 6 . 4 3
MTX was administered as a 1-hour infusion in 50 per cent increments every 2 weeks until individual
tolerance was reached.
individual tolerance. It can be observed that the different manifestations of
toxicity are independent ofthe individual toxic levels with the possible exception
of conjunctivitis, alopecia, nausea, and vomiting, which all occurred more than
twice asfrequently athigherdoses.
The predominant dose limiting toxicity was leukopenia (Table I) occurring in
40 of 49 patients (81 %). Thrombocytopenia was never the single dose limiting
factor. Leukopenia was accompanied by stomatitis in 22 patients (45 %). Nine
patients (19 %) had oral ulcerations as the onlytoxic manifestation. Dose limiting
toxicity was never reached without leukopenia or stomatitis being present. The
kinetics of the most common types of toxicity are summarized in Table III.TOLERANCE TO METHOTREXATE IN CANCER PATIENTS
TABLEIII.-The Kinetics of Common Types of Toxic Manifestations
Onset (days to) Nadir (days to) Duration (days)
Number of A____, A,A
patients Median Range Median Range Median Range
WBC x 103/mm.3
<5 0 . 40 6 3-10 . 8 5-15 . 5 2-14
<30 . 20 . 7 4-13. 8 6-12. 3 1-9
<1*0 . 5 . 8 7-10. 9 9-10. 3 1-8
Platelets x 103/mm.3
<100 9 9 4-12. 11 9-14. 4 2-8
<30 . 4 . 10 6-13. 13 9-14. 3 1-3
Stomatitis 22 . 5 3-6 . 7* 4-8 . 5 2-13
* Maximum intensity
Onset, nadir and duration of leukopenia, thrombocytopenia and stomatitis following the highest
individually tolerated single dose of a 1-hour infusion ofmethotrexate.
Oral toxicity occurred within 3 to 6 days after MTX administration. Leukopenia
started at a median of 6 days, proceeded to a nadir on day 8 and recovered by day
13. In 5 patients, a second nadir of leukopenia was observed, occurring 13-20
days after exposure toMTX, always less pronounced than the first nadir. Throm-
bocytopenia occurred by day 9 (median), reached a nadir on day11, and lasted
until day 14. However, considerable variation in the time of onset and nadir,
and the duration of depression of both cell elements was found. In some patients
the fall in platelet levels was followed by "rebound " thrombocytosis before
return to pretreatment levels. In 16 patients the platelet count rose to above
600,000/mm.3 and of these, 9 patients had a count above 800,000/mm.3 with a
maximum count of 1,220,000/mm.3 on day 15 in1 patient. No similar pronounced
rebound was observed for leukocytes. The minimum reticulocyte count was
observed from 2-7 days after MTX administration (median 5 days). Three
patients died with infection in the presence of pronounced haematologic toxicity
on day 7, 8, and 11, respectively, after exposure to the first dose of MTX of 120,
120, and 180 mg./m2. The nadir of the white blood count was 500, 1100, and
200/mm. , and of the platelets, 50,000, 5000, and 3000/mm. . None of these
patients had demonstrable invasion of the bone marrow by tumour cells, or were
exposed to extensive pretreatment radiotherapy. The ages of the patients were
65, 40, and 51 years, respectively. Less common toxic manifestations (Table II)
included reversible erythrodermic rash, conjunctivitis, hepatotoxicity, diarrhea,
and alopecia. The hepatic toxicity was evidenced by transient elevation of
SGOT (range, 63 to 107; normal < 45 Karmen units) with a peak elevation occur-
ring after 6 to 10 days and a return to normal within 15 to 20 days. In addition,
2 patients demonstrated hyperbilirubinemia with maximums of 6-5 mg./100 ml.
and 5-4 mg./100 ml., respectively. One of these patients who had a biopsy-
proven diagnosis of liver cirrhosis before treatment, but normal liver chemistries
at the time ofreciving a MTX dose of120 mg./m2, died on day 16 in hepatic failure.
No biochemical abnormalities had been noted following the preceding dose of
80 mg./m2.
Prediction of tolerance to MTX.-The wide spread of individual tolerance to
MTX makes it desirable to define predictive factors. When the patient, with age
range 26 to 75 years and median age 54, were divided into 2 groups, 1 with "low "
(80 to 120 mg./m2) and 1 with "high" (180 to 900 mg./m2) tolerance to MTX,
the patient's age represented the only recognizable difference between the 2
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groups. Patients with high tolerance were significantly younger than patients
with lower tolerance to MTX (P < 0.001). Cachexia, as defined by weight loss
from onset of disease until treatment with MTX, pretreatment serum albumin
levels, and pretreatment serum folate showed no correlation with the development
ofMTX toxicity (Table IV). Furthermore, previous myelosuppressive treatment
such as radiotherapy and chemotherapy did not appear to influence tolerance to
MTX (Table V).
Therapeutic effect.-Evaluation of antitumour effect in the 49 patients is
shown in Table VI. Twenty-six patients had measurable lesions. Partial
TABLE IV.-Predictive Factors ofMTX Tolerance
Age (years)
Serum folic acid activity (ng./ml.)
Serum albumin (g./100 ml.)
Weight loss (kg.)
Patients first toxic at
80-120 mg./m2 180-900 mg./m2
Median Range Median Range
61 40-75 49 26-67
2-1 1-0-4x8 2*2 1-1-4 5
3-3 2-2-4-8 3-3 2-3-4-5
12-5 3 0-20-2 13-3 0-25 0
Age, pretreatment serum folic acid activity, serum albumin, and weight loss as related to low
(80-120 mg./m2) and high (180-900 mg./m2) tolerance to methotrexate.
TABLE V.-Correlation between Previous Treatment and Methotrexate Tolerance
No previous treatment
Radiation .
Chemotherapy
Radiation and chemotherapy
Number of
patients
20
17
4
8
Patients first toxic at
Median Range
(mg./m2) (mg./m2)
120 80-400
120 50-600
180 120-600
120 80-900
MTX was administered every 2 weeks as a 1-hour infusion in 50 per cent increments until individual
tolerance was reached.
TABLE VI.-Diagnosis and Response to I.V. Methotrexate in Patients
with Solid Tumours
Diagnosis
Bronchogenic carcinoma
Squamous cell
Anaplastic cell
Oat cell .
Adenocarcinoma
Squamous cell of the head and neck
Oesophagus (squamous cell carcinoma)
Penis (squamous cell carcinoma)
Ovary (papillary adenocarcinoma).
Rhabdomyosarcoma
Thyroid (poorly differentiated
carcinoma
Testis (embryonal cell carcinoma)
Prostate (adenocarcinoma)
Mesothelioma
Total
Total
number
of
patients
20
9
6
1
4
19
2
2
1
1
1
1
1
1
49
Patients
with
measurable
lesions
7
1
4
0
2
16
1
2
0
0
0
1
1
0
28
Response
>50
Progression Static per cent
1
0
1
0
0
2
0
0
3
1
0
0
0
1
12
1
1
5
1
3
0
1
2
0
1
1
16
1
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responses were noted in a total of 10 patients, 5 with bronchogenic carcinoma, 2
with head and neck tumours, 1 with penile carcinoma, and 1 with prostatic car-
cinoma. Progression of disease occurred in 2 patients. Most patients, after
determination ofindividual tolerance, were continued on a subsequent treatment
programme of MTX and leukovorin. This accounts for the high proportion of
patients with static disease and precludes evaluation of the duration of response
achieved by methotrexate alone in the present schedule.
DISCUSSION
The data obtained in the present clinical study demonstrate that a wide spread
of tolerance to MTX exists in man when MTX is administered i.v. as a 1-hour
infusion. Tolerance to MTX in the 49 patients ranged from 50 mg./m2 to
900 mg./m2. Similar variationofdrugtolerancehas also beenobserved by Papac,
Lefkowitz and Bertino (1967) in a small series of patients using a schedule of
MTX or 0-8 mg./kg. or 30 mg./m2 every 4 days until stomatitis and leukopenia
developed. Ofmanyfactors correlatedto the age ofthe patient, with the younger
age group tolerating a higher median dose ofMTX. One possible explanation for
this phenomenon is the decreased glomerular filtration rate as measured by
endogenous creatinine clearance occurring {in elderly patients (Hansen, Kamp-
mann and Laursen, 1970) which is not recognized by standard parameters of
renal function tests such as BUN and/or serum creatinine. Because MTX is
mainly eliminated by glomerular filtration, impairment of renal function increases
serum concentration of MTX and prolongs the exposure time to MTX, resulting
in increased toxicity (Ojima et al., 1970).
However, other phenomena more directly related to the mechanism of action
of MTX might also contribute to the variability of individual drug tolerance.
An inverse correlation between toxicity from MTX and levels of intestinal folic
reductase in rats and mice hasbeen demonstrated (Werkheiser, 1961). In addition
it has been suggested by Werkheiser (1963) that differential permeability through
cell membranes is responsible for the differential sensitivity of dividing cells in
which the concentration of folic acid reductase is comparable. Furthermore,
the initial rate of uptake of the drug as well as the capacity ofthe cells to retain
MTX has varied among different patients (Bertino, 1963). Additional factors
for the variability of MTX tolerance in humans include drug interaction between
MTX and other pharmacologic agents administered at the same time. For
example, it has been shown that riboflavin competitively inhibits the carrier-
mediated influx of MTX into the L1210 mouse leukaemia cell (Lichtenstein and
Goldmann, 1970). Recent data have also indicated that organic acids such as
acetylsalycilic and para-aminohippuric acid inhibit a renal tubular mechanism of
MTX excretion in humans (Liegler et al., 1969). In addition, salicylates, as well as
sulfathiazole, decrease the binding capacity of serum protein by an average of
30 % and 28 %, respectively (Leigler et al., 1969). It has also been demonstrated
in mice that antimicrobial agents such as neomycin and sulfathiazole reduce the
metabolism of MTX in the intestinal tract by decreasing the intestinal flora
(Zaharko, Bruckner, and Oliverio, 1969). Further detailed controlled human
pharmacologic studies are indicated for clarification ofsome ofthese problems.
The findings of subnormal levels of folic acid activity with a median value of
2* 1 ng./ml. inpatientswith metastatic cancer confirms previousreports (Hellmann,
Iannotti, and Bertino (1965), Magnus (1967), Rama Rao et al. (1965). The lack
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of correlation between pretreatment serum folate and maximum tolerated dose of
MTX might reflect limitations in the correlation of serum folate to the intra-
cellular folate pool. In this regard it has been noted that levels of folic acid
activity in red cells are normal in cancer patients even though serum folate is
reduced (Magnus, 1967).
The kinetics of haematologic toxicity encountered in the present study are
analogous to those described by Condit and his colleagues (Condit, 1960; Condit
et al., 1960, 1962) who observed a different kinetic pattern for leukocytes, thrombo-
cytes, and erythrocytes following a single large dose ofMTX. Rebound thrombo-
cytosis has also been previously noted; its origin is somewhat obscure; it has
been speculated that it reflects the activity of a thrombopoietin (Ogston, Dawson,
and Philip, 1968).
The frequency ofhepatic abnormalities occurring after administration ofMTX
is in accordance with observations by others (Gottlieb and Serpick, 1970;
Hersh et al., 1966) and might be even higher than noted if studies were obtained
daily after MTX. Acute hepatotoxicity of clinical importance, however, is
uncommon, and was limited to hepatic coma in a patient with pre-existing biopsy-
proven hepatic cirrhosis. A similar case ofdrug related death in hepatic coma in a
patient with cirrhosis has been reported by Lane (1968). This emphasizes that
MTX should be used with utmost caution in patients with pre-existing, definite
impairment of hepatic function.
The high proportion of toxic manifestations observed at low single dosage of
MTX, including lethal haematologic toxicity in 3 patients after administration of
120, 120, and 180 mg./m2 indicates that initial single doses of 200 mg./m2 pre-
viously reported by Condit et al. (1962) are not safe. Some of this discrepancy
may be related to the infusion period of 1 hour in this study leading to more
prolonged exposure of sensitive tissue to MTX in our study compared with the
i.v. " push " administration used by Condit. Based on the present data, 80
mg./m2 by 1 hour infusion is the highest recommended starting dose ofparenteral
administration of MTX at widely spaced intervals.
It is possible that the life-threatening toxicity observed at an initial MTX
dose of 120 mg./m2 and 180 mg./m2 compared with the same dose level given after
exposure to a nontoxic dosage is elicited by induction of adaptive dihydrofolic
reductase which might bind MTX at the subsequent exposure. Such a hypothesis
is supportedby studies ofBertino et al. (1962, 1963) indicating that both leukaemic
and non-leukaemic leukocytes and erythrocytes develop high levels ofdihydrofolic
reductase after treatment withMTX.
The study was primarily designed for determination of host tolerance, and
most of the tumours were not measurable. Against this background, it is note-
worthy that objective tumour response was observed in patients with bronchogenic
carcinoma, head and neck tumours, prostatic cancer, and penile cancer. This
confirms the wide spectrum of tumours sensitive to MTX. It should be stressed
that widely spaced doses of MTX do not appear to be optimal as a schedule for
treatment of solid tumours. It stands to reason that the therapeutic index of
this agent can be improved either by more frequent administration ofMTX alone
or followed by leukovorin " rescue " (Capizzi et al., 1970; Hryniuk and Bertino,
1969; Mitchell et al., 1968; Schwarzenberg et al., 1969) or, as suggested by Schabel
(1969), by using the cell cycle specific drug MTX in combination with a cell cycle
non-specific agent such as an alkylating agent.TOLERANCE TO METHOTREXATE IN CANCER PATIENTS 305
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